Free Trial

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives $112.38 Average PT from Analysts

Viking Therapeutics logo with Medical background

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) has been assigned an average rating of "Buy" from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $112.38.

VKTX has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Viking Therapeutics in a research report on Tuesday, June 4th. BTIG Research upped their price target on Viking Therapeutics from $100.00 to $125.00 and gave the company a "buy" rating in a research report on Tuesday, March 26th. Jefferies Financial Group initiated coverage on Viking Therapeutics in a research report on Thursday, March 7th. They set a "buy" rating and a $110.00 price target on the stock. William Blair reissued an "outperform" rating on shares of Viking Therapeutics in a research report on Friday, February 23rd. Finally, StockNews.com raised Viking Therapeutics to a "sell" rating in a research report on Friday, May 31st.

Get Our Latest Stock Analysis on Viking Therapeutics

Insider Transactions at Viking Therapeutics

In related news, COO Marianna Mancini sold 281,425 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the completion of the sale, the chief operating officer now owns 348,508 shares in the company, valued at approximately $27,413,639.28. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Viking Therapeutics news, CFO Greg Zante sold 66,756 shares of the firm's stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total value of $4,986,005.64. Following the completion of the sale, the chief financial officer now owns 174,854 shares in the company, valued at approximately $13,059,845.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Marianna Mancini sold 281,425 shares of the firm's stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total value of $22,136,890.50. Following the completion of the sale, the chief operating officer now owns 348,508 shares of the company's stock, valued at approximately $27,413,639.28. The disclosure for this sale can be found here. 4.70% of the stock is currently owned by corporate insiders.


Institutional Trading of Viking Therapeutics

A number of hedge funds have recently modified their holdings of VKTX. Massmutual Trust Co. FSB ADV bought a new stake in shares of Viking Therapeutics in the 1st quarter worth approximately $25,000. Lindbrook Capital LLC lifted its position in shares of Viking Therapeutics by 370.7% in the 1st quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 278 shares during the period. Wetzel Investment Advisors Inc. bought a new position in Viking Therapeutics in the 4th quarter valued at $37,000. LifeSteps Financial Inc. bought a new position in Viking Therapeutics in the 1st quarter valued at $37,000. Finally, Spire Wealth Management bought a new position in Viking Therapeutics in the 1st quarter valued at $61,000. Institutional investors own 76.03% of the company's stock.

Viking Therapeutics Trading Up 4.6 %

Shares of Viking Therapeutics stock traded up $2.31 on Friday, reaching $52.74. 7,218,146 shares of the company were exchanged, compared to its average volume of 4,912,424. The stock has a fifty day moving average price of $64.93 and a 200-day moving average price of $50.12. The firm has a market capitalization of $5.82 billion, a price-to-earnings ratio of -56.71 and a beta of 1.04. Viking Therapeutics has a fifty-two week low of $8.28 and a fifty-two week high of $99.41.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. During the same period last year, the business earned ($0.25) EPS. On average, equities analysts anticipate that Viking Therapeutics will post -1.08 earnings per share for the current fiscal year.

Viking Therapeutics Company Profile

(Get Free Report

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Featured Articles

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

→ The asset beating inflation by 4x (From Colonial Metals) (Ad)

Should you invest $1,000 in Viking Therapeutics right now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

How to Navigate Stock Downgrades
CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines